ADC development requires analytical strategies capable of balancing speed, reproducibility, and molecule-specific optimization across increasingly complex development programs.
This article explores how Samsung Biologics applies a platform-based analytical development approach for ADCs within an integrated end-to-end CDMO model spanning late discovery through commercial manufacturing.
Key highlights include:
Cross-modality analytical framework that integrates antibody and ADC analysis
High-quality data generation, proactive risk management, and support progress toward IND and beyond
A balanced approach combining platform methods, structured feasibility assessments, and targeted customization to improve readiness and predictability
🔗 Read more (Japanese)
ADC development requires analytical strategies capable of balancing speed, reproducibility, and molecule-specific optimization across increasingly complex development programs.
This article explores how Samsung Biologics applies a platform-based analytical development approach for ADCs within an integrated end-to-end CDMO model spanning late discovery through commercial manufacturing.
Key highlights include:
- Cross-modality analytical framework that integrates antibody and ADC analysis
- High-quality data generation, proactive risk management, and support progress toward IND and beyond
- A balanced approach combining platform methods, structured feasibility assessments, and targeted customization to improve readiness and predictability
🔗 Read more (Japanese)
Share article
Related Content